COYA
Coya Therapeutics Inc

1,059
Mkt Cap
$128.48M
Volume
178,412.00
52W High
$8.29
52W Low
$4.65
PE Ratio
-5.57
COYA Fundamentals
Price
$6.10
Prev Close
$6.14
Open
$6.03
50D MA
$6.19
Beta
1.16
Avg. Volume
179,946.47
EPS (Annual)
-$0.9765
P/B
3.77
Rev/Employee
$444,257.63
Loading...
Loading...
News
all
press releases
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·1d ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages
Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·22d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital
Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Friday...
MarketBeat·24d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·25d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Stock Price Expected to Rise, BTIG Research Analyst Says
BTIG Research increased their price objective on Coya Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday...
MarketBeat·26d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday...
MarketBeat·27d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Misses Estimates By $0.12 EPS
Coya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·27d ago
News Placeholder
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·28d ago
News Placeholder
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced...
Business Wire·1mo ago

Latest COYA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.